AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Hypocretin neuropeptide precursor

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We use our state-of-the-art dedicated workflow for designing focused libraries for receptors.

 Fig. 1. The sreening workflow of Receptor.AI

This process includes extensive molecular simulations of the receptor in its native membrane environment, along with ensemble virtual screening that accounts for its conformational mobility. In the case of dimeric or oligomeric receptors, the entire functional complex is modelled, identifying potential binding pockets on and between the subunits to encompass all possible mechanisms of action.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

O43612

UPID:

OREX_HUMAN

Alternative names:

Hypocretin; Orexin precursor; Prepro-orexin; Preprohypocretin

Alternative UPACC:

O43612

Background:

The Hypocretin neuropeptide precursor, also known as Orexin precursor, plays a pivotal role in regulating food intake and sleep-wakefulness, suggesting its broader involvement in energy metabolism, autonomic function, hormonal balance, and body fluid regulation. It binds to orexin receptors HCRTR1/OX1R and HCRTR2/OX2R, stimulating food intake and modulating pituitary luteinizing hormone secretion.

Therapeutic significance:

Narcolepsy 1, a neurological disorder characterized by excessive daytime sleepiness and cataplexy, is linked to variants affecting the Hypocretin gene. The disorder is associated with a deficient orexin system, highlighting the therapeutic potential of targeting this protein in narcolepsy treatment strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.